Lyra Therapeutics Inc
LYRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.95M
Close$
$-3.16
1760.6% downside
Current Fair Value
1760.6% downsideOvervalued by 1760.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.95 Million |
|---|---|
| Enterprise Value | $29.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-18.62 |
| Beta | 0.71 |
| Outstanding Shares | 15,534,730 |
Return
| Return on Equity | 269.84% |
|---|---|
| Return on Assets | -80.09% |
| Return on Invested Capital | -120.50% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.03 |
| Price to Sales | - |
| Price to Book Ratio | -0.19 |
| Enterprise Value to Revenue | 73.32 |
| Enterprise Value to EBIT | -0.91 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.44 |
| Debt to Equity | -3.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-1.54
Average shareholder expectationRevenue Estimate
$99,500
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-1.63
Average shareholder expectationRevenue Estimate
$99,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.56%▼ 1.33% |
|---|---|
| Total Invested | $747,316▼ 74.53% |
| Investors Holding | 22▼ 3.00% |
ESG Score
No data